EpicentRx, a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, has raised an USD35m Series D financing using Biotech Alliances International, a Silicon Valley based life-science focused investment bank, it was reported on Friday.
This funding round will be divided into three tranches and its purpose is to progress the late-stage clinical development of EpicentRx's lead anticancer agent, RRx-001, and proprietary transgene-enhanced oncolytic adenoviral platform technology. The Series D brings the total capital raised by the company to around USD77m.
RRx-001 is a small molecule immunotherapy aimed at the CD47 – SIRP alpha axis. Presently, the drug is being assessed in combination with platinum doublet chemotherapy in the Phase three REPLATINUM trial intended for the treatment of third-line and beyond small cell lung cancer (SCLC).
Revance proposes to launch public offering of common stock
Nektar Therapeutics names new senior vice president and chief commercial officer
Phathom Pharmaceuticals starts phase three vonoprazan clinical trial
KalVista Pharmaceuticals incurs higher net loss of USD5.9m for fiscal second quarter
Appili Therapeutics Names Balboni as CEO
Seattle Genetics, Astellas Forge Clinical Trial Collaboration with US Merck to Evaluate Enfortumab